Dear all, I performed sequence capture of target exons using NimbleGen SeqCap EZ strategy. Now I have to proceed to emPCR (Lib L). Should I denature my for 95 C degrees for 2 minutes?
-
-
No you don't, after LM-PCR only 1 of the strands will be able to get PCRed on the bead. -
Ok, thank you Zaag. May I ask you how many copy per bead do you use in emPCR lib L? I would start trying 1 cpb since it is the first time that I perform this emPCR. Do you have any suggestion?Comment
-
After sequence capture I usually end up between 1 and 2 cpb; so if you measured your sample with a Qubit before calculating the nr of molecules my guess would be that 1cpb would be a safe number.
Usually I do one SVE with 1 cpb and one with 2 cpb and after calculating enrichment I choose a cpb for my bulk emulsion.Comment
-
Can I ask you what is SVE?Comment
-
That would be a small volume emulsion. They come in three sizes, small medium and large.Comment
-
Ok.Thank you very much for your reply. I was wondering if you also perform SeqCap EZ Choice...I have a lot of question regarding this method but I don't think many people of this forum perform SeqCap and then run on a GS Junior platformComment
-
Yeah we do that but on the 454-FLX+ so no junior here. I am not sure what exactly are the differences regarding emPCR and such, but if you have questions just mail me, or ask them here (mail is faster answer).Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment